These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15746529)

  • 1. Type 2 transglutaminase and cell death.
    Piacentini M; Amendola A; Ciccosanti F; Falasca L; Farrace MG; Mastroberardino PG; Nardacci R; Oliverio S; Piredda L; Rodolfo C; Autuori F
    Prog Exp Tumor Res; 2005; 38():58-74. PubMed ID: 15746529
    [No Abstract]   [Full Text] [Related]  

  • 2. Transglutaminase 2 at the crossroads between cell death and survival.
    Piacentini M; D'Eletto M; Falasca L; Farrace MG; Rodolfo C
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():197-246. PubMed ID: 22220475
    [No Abstract]   [Full Text] [Related]  

  • 3. Transglutaminases in wound healing and inflammation.
    Verderio EA; Johnson TS; Griffin M
    Prog Exp Tumor Res; 2005; 38():89-114. PubMed ID: 15746531
    [No Abstract]   [Full Text] [Related]  

  • 4. Tissue transglutaminase (TG2) acting as G protein protects hepatocytes against Fas-mediated cell death in mice.
    Sarang Z; Molnár P; Németh T; Gomba S; Kardon T; Melino G; Cotecchia S; Fésüs L; Szondy Z
    Hepatology; 2005 Sep; 42(3):578-87. PubMed ID: 16108039
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transglutaminase and cell-survival signaling.
    Singh US; Pan J
    Prog Exp Tumor Res; 2005; 38():75-88. PubMed ID: 15746530
    [No Abstract]   [Full Text] [Related]  

  • 6. Validity of mouse models for the study of tissue transglutaminase in neurodegenerative diseases.
    Bailey CD; Graham RM; Nanda N; Davies PJ; Johnson GV
    Mol Cell Neurosci; 2004 Mar; 25(3):493-503. PubMed ID: 15033177
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue transglutaminase contributes to disease progression in the R6/2 Huntington's disease mouse model via aggregate-independent mechanisms.
    Bailey CD; Johnson GV
    J Neurochem; 2005 Jan; 92(1):83-92. PubMed ID: 15606898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 'Tissue' transglutaminase ablation reduces neuronal death and prolongs survival in a mouse model of Huntington's disease.
    Mastroberardino PG; Iannicola C; Nardacci R; Bernassola F; De Laurenzi V; Melino G; Moreno S; Pavone F; Oliverio S; Fesus L; Piacentini M
    Cell Death Differ; 2002 Sep; 9(9):873-80. PubMed ID: 12181738
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transglutaminase type II is a key element in the regulation of the anti-inflammatory response elicited by apoptotic cell engulfment.
    Falasca L; Iadevaia V; Ciccosanti F; Melino G; Serafino A; Piacentini M
    J Immunol; 2005 Jun; 174(11):7330-40. PubMed ID: 15905580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transglutaminase 2 dysfunctions in the development of autoimmune disorders: celiac disease and TG2-/- mouse.
    Szondy Z; Korponay-Szabó I; Király R; Fésüs L
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():295-345. PubMed ID: 22220477
    [No Abstract]   [Full Text] [Related]  

  • 11. Some lessons from the tissue transglutaminase knockout mouse.
    Sarang Z; Tóth B; Balajthy Z; Köröskényi K; Garabuczi E; Fésüs L; Szondy Z
    Amino Acids; 2009 Apr; 36(4):625-31. PubMed ID: 18584284
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transglutaminase-mediated remodeling of the human erythrocyte membrane skeleton: relevance for erythrocyte diseases with shortened cell lifespan.
    Lorand L; Murthy SN; Khan AA; Xue W; Lockridge O; Chishti AH
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():385-414. PubMed ID: 22220479
    [No Abstract]   [Full Text] [Related]  

  • 13. Transglutaminases in neurodegenerative disorders.
    Bailey CD; Tucholski J; Johnson GV
    Prog Exp Tumor Res; 2005; 38():139-57. PubMed ID: 15746534
    [No Abstract]   [Full Text] [Related]  

  • 14. Transglutaminase 2: biology, relevance to neurodegenerative diseases and therapeutic implications.
    Grosso H; Mouradian MM
    Pharmacol Ther; 2012 Mar; 133(3):392-410. PubMed ID: 22212614
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tissue transglutaminase and its role in human cancer progression.
    Li B; Cerione RA; Antonyak M
    Adv Enzymol Relat Areas Mol Biol; 2011; 78():247-93. PubMed ID: 22220476
    [No Abstract]   [Full Text] [Related]  

  • 16. Type 2 transglutaminase in neurodegenerative diseases: the mitochondrial connection.
    Malorni W; Farrace MG; Rodolfo C; Piacentini M
    Curr Pharm Des; 2008; 14(3):278-88. PubMed ID: 18220838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATP-binding cassette transporter 1 and transglutaminase 2 act on the same genetic pathway in the apoptotic cell clearance.
    Iadevaia V; Rinaldi A; Falasca L; Pucillo LP; Alonzi T; Chimini G; Piacentini M
    Cell Death Differ; 2006 Nov; 13(11):1998-2001. PubMed ID: 16691213
    [No Abstract]   [Full Text] [Related]  

  • 18. Possible involvement of transglutaminase-catalyzed reactions in the physiopathology of neurodegenerative diseases.
    Martin A; Giuliano A; Collaro D; De Vivo G; Sedia C; Serretiello E; Gentile V
    Amino Acids; 2013 Jan; 44(1):111-8. PubMed ID: 21938398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminases in inflammation and fibrosis of the gastrointestinal tract and the liver.
    Elli L; Bergamini CM; Bardella MT; Schuppan D
    Dig Liver Dis; 2009 Aug; 41(8):541-50. PubMed ID: 19195940
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "Tissue" transglutaminase and apoptosis.
    Autuori F; Farrace MG; Oliverio S; Piredda L; Piacentini M
    Adv Biochem Eng Biotechnol; 1998; 62():129-36. PubMed ID: 9755643
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.